| pubmed-article:14550277 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:14550277 | lifeskim:mentions | umls-concept:C0302600 | lld:lifeskim |
| pubmed-article:14550277 | lifeskim:mentions | umls-concept:C0012544 | lld:lifeskim |
| pubmed-article:14550277 | lifeskim:mentions | umls-concept:C1533691 | lld:lifeskim |
| pubmed-article:14550277 | lifeskim:mentions | umls-concept:C0679622 | lld:lifeskim |
| pubmed-article:14550277 | lifeskim:mentions | umls-concept:C0205314 | lld:lifeskim |
| pubmed-article:14550277 | lifeskim:mentions | umls-concept:C1515655 | lld:lifeskim |
| pubmed-article:14550277 | lifeskim:mentions | umls-concept:C2267018 | lld:lifeskim |
| pubmed-article:14550277 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:14550277 | pubmed:dateCreated | 2003-10-10 | lld:pubmed |
| pubmed-article:14550277 | pubmed:abstractText | Bisphosphonates (BP) are powerful inhibitors of bone resorption and are widely used in the treatment of patients with metastasis-induced osteolysis. In the present study, we show that a novel non-nitrogen-containing BP (BP7033) that exhibits antitumor activity is a potent inhibitor of both in vivo and in vitro angiogenesis. When administered to mice, BP7033 inhibited tumoral angiogenesis (65% at 0.06mg/injection) as well as tumor growth (65% at 0.006mg/injection) in a tumor model of A431 cells xenografted in nude mice, with no sign of toxicity. Additionally, in vivo angiogenesis induced by vascular endothelial growth factor-containing Matrigel implants was reduced by 90% in the presence of BP7033 (0.6mg/plug). In vitro, BP7033 inhibited proliferation of human umbilical vein endothelial cells (HUVEC) (IC(50) value 3x10(-4) M) and completely prevented the formation of capillary-like tubules by HUVEC in Matrigel. Moreover, treatment of A431 cells by BP7033 induced an inhibition of Ras processing and a decrease in the secretion of both vascular endothelial growth factor and matrix metalloproteinase-2, two well-known stimulators of the proliferation and migration of endothelial cells. These findings indicate that this new BP compound has marked antiangiogenic properties and thus represents a promising candidate for treatment of malignant diseases with an angiogenic component. | lld:pubmed |
| pubmed-article:14550277 | pubmed:language | eng | lld:pubmed |
| pubmed-article:14550277 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14550277 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:14550277 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14550277 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14550277 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14550277 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14550277 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14550277 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14550277 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14550277 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14550277 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14550277 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:14550277 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:14550277 | pubmed:issn | 0006-291X | lld:pubmed |
| pubmed-article:14550277 | pubmed:author | pubmed-author:LecouveyMarcM | lld:pubmed |
| pubmed-article:14550277 | pubmed:author | pubmed-author:LerouxYvesY | lld:pubmed |
| pubmed-article:14550277 | pubmed:author | pubmed-author:Di... | lld:pubmed |
| pubmed-article:14550277 | pubmed:author | pubmed-author:KraemerMichel... | lld:pubmed |
| pubmed-article:14550277 | pubmed:author | pubmed-author:LedouxDominiq... | lld:pubmed |
| pubmed-article:14550277 | pubmed:author | pubmed-author:Hamma-Kourbal... | lld:pubmed |
| pubmed-article:14550277 | pubmed:author | pubmed-author:OudarOlivierO | lld:pubmed |
| pubmed-article:14550277 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:14550277 | pubmed:day | 24 | lld:pubmed |
| pubmed-article:14550277 | pubmed:volume | 310 | lld:pubmed |
| pubmed-article:14550277 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:14550277 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:14550277 | pubmed:pagination | 816-23 | lld:pubmed |
| pubmed-article:14550277 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:14550277 | pubmed:meshHeading | pubmed-meshheading:14550277... | lld:pubmed |
| pubmed-article:14550277 | pubmed:meshHeading | pubmed-meshheading:14550277... | lld:pubmed |
| pubmed-article:14550277 | pubmed:meshHeading | pubmed-meshheading:14550277... | lld:pubmed |
| pubmed-article:14550277 | pubmed:meshHeading | pubmed-meshheading:14550277... | lld:pubmed |
| pubmed-article:14550277 | pubmed:meshHeading | pubmed-meshheading:14550277... | lld:pubmed |
| pubmed-article:14550277 | pubmed:meshHeading | pubmed-meshheading:14550277... | lld:pubmed |
| pubmed-article:14550277 | pubmed:meshHeading | pubmed-meshheading:14550277... | lld:pubmed |
| pubmed-article:14550277 | pubmed:meshHeading | pubmed-meshheading:14550277... | lld:pubmed |
| pubmed-article:14550277 | pubmed:meshHeading | pubmed-meshheading:14550277... | lld:pubmed |
| pubmed-article:14550277 | pubmed:meshHeading | pubmed-meshheading:14550277... | lld:pubmed |
| pubmed-article:14550277 | pubmed:meshHeading | pubmed-meshheading:14550277... | lld:pubmed |
| pubmed-article:14550277 | pubmed:meshHeading | pubmed-meshheading:14550277... | lld:pubmed |
| pubmed-article:14550277 | pubmed:meshHeading | pubmed-meshheading:14550277... | lld:pubmed |
| pubmed-article:14550277 | pubmed:meshHeading | pubmed-meshheading:14550277... | lld:pubmed |
| pubmed-article:14550277 | pubmed:meshHeading | pubmed-meshheading:14550277... | lld:pubmed |
| pubmed-article:14550277 | pubmed:meshHeading | pubmed-meshheading:14550277... | lld:pubmed |
| pubmed-article:14550277 | pubmed:meshHeading | pubmed-meshheading:14550277... | lld:pubmed |
| pubmed-article:14550277 | pubmed:meshHeading | pubmed-meshheading:14550277... | lld:pubmed |
| pubmed-article:14550277 | pubmed:meshHeading | pubmed-meshheading:14550277... | lld:pubmed |
| pubmed-article:14550277 | pubmed:meshHeading | pubmed-meshheading:14550277... | lld:pubmed |
| pubmed-article:14550277 | pubmed:meshHeading | pubmed-meshheading:14550277... | lld:pubmed |
| pubmed-article:14550277 | pubmed:meshHeading | pubmed-meshheading:14550277... | lld:pubmed |
| pubmed-article:14550277 | pubmed:meshHeading | pubmed-meshheading:14550277... | lld:pubmed |
| pubmed-article:14550277 | pubmed:meshHeading | pubmed-meshheading:14550277... | lld:pubmed |
| pubmed-article:14550277 | pubmed:meshHeading | pubmed-meshheading:14550277... | lld:pubmed |
| pubmed-article:14550277 | pubmed:meshHeading | pubmed-meshheading:14550277... | lld:pubmed |
| pubmed-article:14550277 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:14550277 | pubmed:articleTitle | A novel non-containing-nitrogen bisphosphonate inhibits both in vitro and in vivo angiogenesis. | lld:pubmed |
| pubmed-article:14550277 | pubmed:affiliation | Laboratoire d'Oncologie Cellulaire et Moléculaire, UPRES 2360, Université Paris 13, UFR SMBH, Bobigny, France. | lld:pubmed |
| pubmed-article:14550277 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:14550277 | pubmed:publicationType | In Vitro | lld:pubmed |
| pubmed-article:14550277 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14550277 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14550277 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14550277 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14550277 | lld:pubmed |
